Tigenix says rheumatoid arthritis drug appears safe
BRUSSELS Dec 19 (Reuters) - Belgian stem cell research company Tigenix NV said on Wednesday that Cx611, its drug in development to treat rheumatoid arthritis, had produced positive interim safety results in a Phase IIa trial.
TiGenix said only two people in its 53-person study had suffered severe adverse effects and only one had discontinued treatment after three months. The study is set to run for six months and final results are due at the end of April 2013.
- Obama makes rare campaign trail appearance, people leave early
- Two arrested in death of Saudi student in California: report
- Obama makes rare campaign trail appearance, some leave early
- IBM to pay Globalfoundries $1.5 bln to take chip unit off its hands -WSJ
- Former 'American Idol' contestant Joanne Borgella dies at 32